Repeat Injection of Cingal® for Osteoarthritis of the Knee
An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide to Provide Symptomatic Relief of Osteoarthritis of the Knee
Sponsor: Anika Therapeutics, Inc.
This PHASE3 trial investigates Osteoarthritis of the Knee and is currently completed. Anika Therapeutics, Inc. leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anika Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .